Sustained Islet Allograft Function After Peritransplant Treatment Using Exenatide With and Without Everolimus

Transplantation. 2016 Nov;100(11):e117-e118. doi: 10.1097/TP.0000000000001441.
No abstract available

Publication types

  • Letter

MeSH terms

  • Allografts
  • C-Peptide / blood
  • Diabetes Mellitus, Type 1 / blood
  • Diabetes Mellitus, Type 1 / diagnosis
  • Diabetes Mellitus, Type 1 / surgery*
  • Everolimus / adverse effects
  • Everolimus / therapeutic use*
  • Exenatide
  • Glycated Hemoglobin / metabolism
  • Graft Survival / drug effects
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / therapeutic use*
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Islets of Langerhans Transplantation*
  • Peptides / adverse effects
  • Peptides / therapeutic use*
  • Pilot Projects
  • Time Factors
  • Treatment Outcome
  • Venoms / adverse effects
  • Venoms / therapeutic use*

Substances

  • C-Peptide
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Immunosuppressive Agents
  • Peptides
  • Venoms
  • hemoglobin A1c protein, human
  • Everolimus
  • Exenatide